Table 3. Cytogenetic abnormalities in CMML patients with leukemia cutis.
| Reference | Age/Sex | Chromosome abnormality | Genetic mutations | Progression1 | EM |
|---|---|---|---|---|---|
| Longacre et al. (10) | 42/F | 46,XX,der(3),t(8;16)(pll.2;ql3.3) | * | * | * |
| 62/M | 47,XY,+19,iso10 | * | * | * | |
| Mahmood et al. (15) | 95/F | Trisomy 8 | * | * | * |
| Mathew et al. (17) | 71/M | 45,XY,-7[20] | * | AML | * |
| 66/M | 46,XY,del(11)(q13q23)[12]/47,XY,del(11),+21 [8] | * | No | * | |
| 74/M | 47,XY,+mar[7]/49,XY,+11,+2mar[2]/49,XY,i(11)(q10),+2mar[1]/46,XY [10] | * | AML | * | |
| 69/M | 46,XY,t(15;17)(q22q21) [20] | * | * | CNS | |
| 68/F | 46,XX,t(1;5)(p32q12)[9]/46,XX [11] | * | AML | * | |
| Vitte et al. (18) | 62/M | 46,XY,del(20)(q12)[9]/46,XY[14] | * | No | * |
| 76/M | 47,XY,+8 [12]/46,XY [13] | * | AML | * | |
| 5/M | 46,XY,t(5;13)(q13-q15;q12-q13),add(6)(q13)[29]/46,XY[14] | * | No | * | |
| 65/M | 46,XY,del(13)(q14q22)[20] | * | No | * | |
| 60/M | 46,XY,del(7)(q11.2)[13]/47,XY,+21[1]/46,XY[8] | * | No | * | |
| 83/M | 47,XY,dup(3)(q2?1q2?6),+8[6]/46,XY[17]ish(dup)(3)(wcp3+)[5/20] | * | AML | * | |
| 59/F | 47,XX,+8[25] | * | No | * | |
| Dargent et al. (21) | 61/M | 47,XY,+13[10]/46,XY[10] | * | AML | Hepatomegaly; splenomegaly |
| Loghavi et al. (23) | 67/M | 46,XY[20] | KRAS(+) | Monocytosis | Hepatomegaly; splenomegaly |
*, not clearly described in the literature. M/F, male or female; 1, transformation to acute myelogenous leukemia (AML) or disease progression; EM, Extramedullary manifestations; CNS, central nervous system; JMML, Juvenile myelomonocytic leukemia; CMML, chronic myelomonocytic leukaemia.